Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Stifel upgraded Tandem Diabetes(TNDM) to Buy from Hold with a price target of $26, up from $22. For future tubeless entrants, Tandem's tubeless Mobi scored well, with 2028 share ahead of Fit and Mint, the firm tells investors in a research note. Raymond James upgraded Charles Schwab(SCHW) to Strong Buy from Outperform with a $135 price target.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
